AG-012986

AG-012986 is a potent and selective multi-CDK inhibitor targeting CDK1, 2, 4/6, 5, and 9. It demonstrates robust in vitro antiproliferative activity and induces significant tumor growth inhibition in vivo across multiple human xenograft models, associated with Rb hypophosphorylation, cell cycle arrest, and apoptosis. This profile supports its research use in oncology, particularly for studying cell cycle dysregulation and evaluating CDK inhibition as a therapeutic strategy.